Ganirelix

Ganirelix is a synthetic decapeptide GnRH antagonist used in assisted reproductive technology to prevent premature LH surges and unintended ovulation during controlled ovarian hyperstimulation for IVF. Sold under the brand names Antagon (US) and Orgalutran (Europe), it offers rapid onset pituitary suppression without the flare effect associated with GnRH agonists, resulting in shorter stimulation protocols and better patient tolerability.

Ganirelix competitively binds to pituitary GnRH receptors with significantly higher binding affinity (Kd = 0.4 nM) than endogenous GnRH (Kd = 3.6 nM), rapidly suppressing LH and FSH secretion within hours. Multiple D-amino acid substitutions at positions 1, 2, 3, 6, 8, and 10 of the native GnRH decapeptide provide metabolic stability and prolonged receptor occupancy. Unlike GnRH agonists, ganirelix does not trigger receptor downregulation or an initial gonadotropin flare; suppression is immediate and fully reversible upon discontinuation. Steady-state plasma concentrations are achieved after 3 days of daily dosing, maintaining consistent LH suppression throughout the stimulation window.

Phase III trials established ganirelix 0.25 mg daily as the minimal effective dose preventing premature LH surges while optimizing ongoing pregnancy rates. Comparative studies versus leuprolide long protocols demonstrate equivalent clinical pregnancy rates with significantly fewer injection days and lower total FSH dosage. A large European multicenter trial (n=730) confirmed non-inferiority to buserelin long protocol. Post-marketing data indicate lower OHSS incidence versus GnRH agonist protocols, particularly in high-responder patients. Ganirelix is also being studied for endometriosis management.

Peptides commonly paired with Ganirelix for synergistic effects.